J Cancer
2021; 12(12):3587-3596.
doi:10.7150/jca.55173 This issueCite
Review
Advances in cancer treatment: a new therapeutic target, Annexin A2
Zinan Li1,2#, Lifeng Yu1,2#, Baohui Hu1,2, Lianze Chen1,2, Mingyi Jv1,2, Lin Wang1,2, Chenyi Zhou1,2, Minjie Wei1,2,3✉, Lin Zhao1,2✉
1. Department of Pharmacology, School of Pharmacy, China Medical University, No.77 Puhe Road, Shenyang North New Area, Shenyang City, 110122, Liaoning, China. 2. Liaoning Engineering Technology Research Center, China Medical University, No.77 Puhe Road, Shenyang North New Area, Shenyang City, 110122, Liaoning, China. 3. Liaoning Medical Diagnosis and Treatment Center, Liaoning Province, China. #These authors contributed equally to this work.
✉ Corresponding authors: Minjie Wei and Lin Zhao, PhD, Department of Pharmacology, School of Pharmacy, China Medical University, No.77 Puhe Road, Shenyang North New Area, Shenyang 110122, Liaoning, China. E-mail: weiminjiecmucom; lzhaoedu.cn.More
Citation:
Li Z, Yu L, Hu B, Chen L, Jv M, Wang L, Zhou C, Wei M, Zhao L. Advances in cancer treatment: a new therapeutic target, Annexin A2. J Cancer 2021; 12(12):3587-3596. doi:10.7150/jca.55173. https://www.jcancer.org/v12p3587.htm
Annexin A2 (ANXA2) is a calcium regulated phospholipid-binding protein. It is expressed in some tumor cells, endothelial cells, macrophages, and mononuclear cells, affecting cell survival and mediating interactions between intercellular and extracellular microenvironment. Aberrant expression of ANXA2 can be used as a potential predictive factor, diagnostic biomarker and therapeutic target in cancer therapy. Investigators used various technologies to target ANXA2 in a preclinical model of human cancers and demonstrated encouraging results. In this review article, we discuss the diagnosis and prognosis latent capacity of ANXA2 in progressive cancers, focus on the exploration of restorative interventions targeting ANXA2 in cancer treatment. Further, we comment on a promising candidate therapy that is conceivable for clinical translation.
Keywords: Annexin A2, cancer, target, cancer therapy
Citation styles
APA
Li, Z., Yu, L., Hu, B., Chen, L., Jv, M., Wang, L., Zhou, C., Wei, M., Zhao, L. (2021). Advances in cancer treatment: a new therapeutic target, Annexin A2. Journal of Cancer, 12(12), 3587-3596. https://doi.org/10.7150/jca.55173.
ACS
Li, Z.; Yu, L.; Hu, B.; Chen, L.; Jv, M.; Wang, L.; Zhou, C.; Wei, M.; Zhao, L. Advances in cancer treatment: a new therapeutic target, Annexin A2. J. Cancer 2021, 12 (12), 3587-3596. DOI: 10.7150/jca.55173.
NLM
Li Z, Yu L, Hu B, Chen L, Jv M, Wang L, Zhou C, Wei M, Zhao L. Advances in cancer treatment: a new therapeutic target, Annexin A2. J Cancer 2021; 12(12):3587-3596. doi:10.7150/jca.55173. https://www.jcancer.org/v12p3587.htm
CSE
Li Z, Yu L, Hu B, Chen L, Jv M, Wang L, Zhou C, Wei M, Zhao L. 2021. Advances in cancer treatment: a new therapeutic target, Annexin A2. J Cancer. 12(12):3587-3596.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.